Smith & Nephew Stock Rating Reaffirmed by Deutsche Bank (SN)
Smith & Nephew (LON:SN)‘s stock had its “hold” rating restated by investment analysts at Deutsche Bank in a note issued to investors on Thursday, StockRatingsNetwork reports. They currently have a GBX 650 ($10.66) target price on the stock. Deutsche Bank’s price objective suggests a potential downside of 25.33% from the company’s current price.
A number of other analysts have also recently weighed in on SN. Analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew in a research note to investors on Thursday, January 2nd. They now have a GBX 920 ($15.09) price target on the stock. Finally, analysts at BNP Paribas reiterated an “outperform” rating on shares of Smith & Nephew in a research note to investors on Friday, December 6th. They now have a GBX 950 ($15.58) price target on the stock. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of GBX 803.06 ($13.17).
Shares of Smith & Nephew (LON:SN) traded up 0.23% during mid-day trading on Thursday, hitting GBX 870.50. 1,856,669 shares of the company’s stock traded hands. Smith & Nephew has a 52-week low of GBX 683.00 and a 52-week high of GBX 878.00. The stock’s 50-day moving average is GBX 835.8 and its 200-day moving average is GBX 792.9. The company’s market cap is £7.826 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.